Clinical efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus treated with metformin alone

LI Xia; BAI Xiaogang; LIU Xinqi; WEN Juan

Abstract：Objective To investigate the clinical efficacy and safety of sitagliptin therapy in patients with type 2 diabetes mellitus (T2DM) treated with metformin alone.Methods 128 cases of elderly patients with T2DM admitted to our hospital between January 2012 and May 2016, whose blood glucose levels were abnormal after a single metformin treatment, were selected as the subjects. The patients were equally divided into control group and observation group according to the treatment method. Patients in the control group were treated with metformin and pioglitazone, while the observation group was additionally treated with sitagliptin. The course of treatment was 3 months. The levels of blood glucose were compared between the two groups, and the incidence of adverse reactions was compared between the two groups after treatment.Results No significant difference was detected in FPG, 2hPG, HbA1c levels or BMI between the two groups before treatment (P>0.05). The above indexes were different after treatment, and the levels of FPG, 2hPG and HbA1c in the observation group were significantly lower than those in the control group, but BMI in the observation group was higher (P<0.05). The difference was statistically significant (P<0.05). No significant difference was detected in the incidence of adverse reactions between the two groups (P>0.05). The symptoms disappeared after corresponding treatment. No hypoglycemia or other serious adverse reactions occurred.Conclusion Sitagliptin can significantly reduce the FPG, 2hPG and HbA1c levels of elderly patients with T2DM treated with metformin alone. Sitagliptin is quite safe and can be used as a treatment for patients with T2DM.